-他汀类药物的副作用课件.ppt

《-他汀类药物的副作用课件.ppt》由会员分享，可在线阅读，更多相关《-他汀类药物的副作用课件.ppt（60页珍藏版）》请在得力文库 - 分享文档赚钱的网站上搜索。

1、更多医学精品更多医学精品尽在医学吧尽在医学吧 他汀类药物的副作用他汀类药物的副作用除了停药还能作些什么除了停药还能作些什么？中国医学科学院 阜外心血管病医院 Adverse effects of statins:Strategies beyond discontinuationDisclosure（讲前声明）No any interest was involved in this Lecture冠心病冠心病:发展中国家的严峻挑战发展中国家的严峻挑战q WHO2008年报告：心血管病死亡占 全球死亡31%，排名第一(传染病29%)q 17,00万/年死于动脉粥样硬化性疾病 q 80分布在低中等收

2、入国家包括中国 q 我国每年死于冠心病的人数达250万CHD:Severe challenge in developing countries 优化药物治疗是现代冠心病治疗主流优化药物治疗是现代冠心病治疗主流药物药物危险性减少危险性减少(%)(%)5 5年事件发生率年事件发生率(%)(%)无药物治疗无药物治疗020.0阿司匹林阿司匹林2515.0 受体阻滞剂受体阻滞剂2511.3ACEIACEI258.4他汀类药物他汀类药物305.9同时使用上述同时使用上述4 4种药物，可使总的死亡危险性减少种药物，可使总的死亡危险性减少70%70%5 5年中，每治疗年中，每治疗7 7位患者，便可减少位患者，

3、便可减少1 1例主要心血管事件例主要心血管事件Yusuf et al.Rev Cardiovasc Med.2003;4(suppl 3):537-46.Current strategies of medication therapy for coronary heart disease 他汀促进强化调脂与靶目标概念诞生他汀促进强化调脂与靶目标概念诞生 危险等级危险等级TLCTLC开始开始(mg)mg)治疗开始治疗开始(mg)mg)目标值目标值(mg)mg)低危低危:（1010年危险性年危险性5%240240LDL-CLDL-C 160160TCTC 270270LDL-CLDL-C 1901

4、90TC240TC240LDL-C160LDL-C 200200LDL-CLDL-C 130130TC TC 240 240LDL-C LDL-C 160 160TC200TC200LDL-C130LDL-C 160 160LDL-C LDL-C 100 100TC TC 160 160LDL-C LDL-C 100 100TC160TC160LDL-C100LDL-C 120120LDL-CLDL-C880 0TC TC 160160LDL-C LDL-C 880 0TC120TC120LDL-C80LDL-C3ALT3倍倍ULN ULN 19/213219/2132（0.90.9）8/20

5、688/2068（0.40.4）横纹肌溶解横纹肌溶解#3/2230 3/2230（0.10.1）0/22300/2230（0 0）肌病肌病 9/22639/2263（0.40.4）1/22301/2230（0.040.04）因肌肉方面不良反应因肌肉方面不良反应而停药而停药 41/226341/2263（1.81.8）34/223034/2230（1.51.5）Rate of adverse effects occurred in A to Z study不良反应类型不良反应类型TNT研究不良事件发生率与剂量关系 La Rosa JC et al.N Engl J Med 2005;352:14

6、25-1435.阿托伐他汀 10mg阿托伐他汀 80mgP值(n=5,006)(n=4,995)和治疗相关的副反应289(5.8)406(8.1)0.001和治疗相关的肌痛234(4.7)241(4.8)0.72 肌溶解*3(0.06)2(0.04)肝酶升高大于三倍9(0.2)60(1.2)65 yrs)with MI 接受二种降压方案治XZK or或安慰 剂治疗，随访4.5年q 结果与结论：XZK（含洛伐他汀10mg 明显 降低老年心梗后高血压患者的心血管事件Li J-J,Lu Z-L,et al.J Clin Pharmacol 2009;47:947-956.Xuezhikang dec

7、rease CVE in Chinese hypertensive elderly with MI 他汀类副作用他汀类副作用:除了停药还能作些什么？除了停药还能作些什么？他汀类药物之间的转换应用他汀类药物之间的转换应用 Statin switching Statin switchingAdverse effects of statins:Strategies beyond discontinuationStatin switching:a case reportq Case report:1 59-year-old women withCase report:1 59-year-old wom

8、en with heart transplantation 4 years heart transplantation 4 years eraliereralier.q PravastatinPravastatin 20mg/d for 4 years 20mg/d for 4 yearsq After switching from After switching from pravastatinpravastatin to to simvastatinsimvastatin,she developed severe muscular she developed severe muscular

9、 weakness until repeat weakness until repeat hemodialysishemodialysis Sochman J,Podzimkova M.Int J Cardiol 2005;99:145-146.相对亲水性相对亲水性*Statin switching:basic mechanism他汀药效基团他汀药效基团OONNSNOHOHOOCH3CH3CH3FCH3Ca(3R,5S)亲水的磺酸基团亲水的磺酸基团Buckett et al.,(2000);McTaggart et al.,(2001)相对亲脂性相对亲脂性*-1.0-0.50.00.51.01

10、.52.0瑞舒伐他汀瑞舒伐他汀西立伐他汀西立伐他汀辛伐他汀辛伐他汀氟伐他汀氟伐他汀阿托伐他汀阿托伐他汀普伐他汀普伐他汀*log D at pH 7.4肝外扩散肝外扩散分布少分布少肝内肝内 CYP代谢少代谢少Cell-selective action of Water-loving and water-hating statin 普伐他汀普伐他汀ML-236B静注静注CC1414标记美百乐镇标记美百乐镇 及及 ML-236B ML-236B 后大鼠全身放射显影照片后大鼠全身放射显影照片Arai M,et al.Annu Rep Sankyo Res Lab 1988;1:40.普伐他汀普伐他汀在

11、肝脏高度选择性分布在肝脏高度选择性分布High-degree selective action in liver following pravastatin administrationFDA报道他汀发生肌毒性事件他汀类他汀类氟伐氟伐他汀他汀普伐普伐他汀他汀洛伐洛伐他汀他汀阿托伐阿托伐他汀他汀辛伐辛伐他汀他汀西立伐西立伐他汀他汀横纹肌溶解0.61.21.21.23.688.7肌病0.61.44.20.51.66.5肌炎0.21.03.90.61.311.5肌痛2.75.816.48.07.546.3FDA report data on fileStatin-related toxic myop

12、athy:Are all statins same?他汀类副作用他汀类副作用:除了停药还能作些什么？除了停药还能作些什么？非他汀降脂药物的替换应用非他汀降脂药物的替换应用 Nonstatin alternatives Nonstatin alternativesAdverse effects of statins:Strategies beyond discontinuation非他汀降脂药物替换应用的临床选择非他汀降脂药物替换应用的临床选择q 烟酸q 多廿烷醇q Red yeast rice Red yeast rice（血脂康）血脂康）q 3-脂肪酸q 依折麦布Clinical selec

13、tion of nonstatin lipid-lowering drugs烟酸类调脂药物的作用特点与应用qB族维生素(vitamin B3),大剂量有降脂作用；适用高TG 血症，低HDL-C血症或以TG升高为主混合型高脂血症q速释剂烟酸不良反应明显，现已不用。缓释型烟酸不 良反应明显减轻，较易耐受 q临床试验CDP,CLAS-I,FATS,HATS,ARBITER2 等证实，烟酸降低主要冠脉事件减少总死亡率q常见不良反应：颜面潮红、高血糖、高尿酸（或痛风）、上消化道不适等。绝对禁忌证为慢性肝病和严重痛风；相对禁忌证为溃疡病、肝毒性和高尿酸血症Clinical features and app

14、lication of Niacin-derived drugsStudy on extended niacin applicationqDesign:Design:Randomized,double-blind,placebo controlled Randomized,double-blind,placebo controlled multicenter,24-week trialmulticenter,24-week trialqDrug:Drug:Combination of Niacin 2000mg/laropiprant 40mg Combination of Niacin 20

15、00mg/laropiprant 40mgqResults:Results:LDL-C 18%LDL-C 18%Incidence and intensity of flushing were significantly reduced Incidence and intensity of flushing were significantly reduced compared with Niacin 2000mg pared with Niacin 2000mg alone.qConclusion:Conclusion:Combination of Niacin/Combination of

16、 Niacin/laropiprantlaropiprant was generally was generally well tolerated by adults with well tolerated by adults with dyslipidemiadyslipidemia.Perry CM.Drugs 2009;69:1665-1679.多廿烷醇调脂治疗临床应用文献汇总q 作用机制：通过腺苷酸激酶选择性阻断HMG-CoA还原 酶的活性（他汀完全阻断HMG-CoA合成酶）q 调脂作用：10 mg/d:LDL-C 17%;HDL-C+5%20mg/d:LDL-C 24%;HDL-C+

17、18%q 证据：1）肝酶异常者（ALT45U/L）应用无恶化现象 2）迄今无肌病及肌溶解报道J Gerontol Med Sci 2001;13:1-9;Curr Ther Res 1996;57:118-127.Red yeast rice（红曲）红曲）for dislipidemia in a statin-intolerant patients:a randomize trialqDesign Design（设计）设计）:Randomized,controlled trialqPatientsPatients（患者）患者）:62 名他汀肌病停药者qTherapy Therapy（治疗）治

18、疗）:Rid yeast rice 1800mg(Sylvan bioproducts,Kittanning,Pennsylvania)or placebo(n=31 respectively)BidqFollow-upFollow-up（随访）随访）:24 weeks,primary outcome:LDL-C;secondary outcome:TC,HDL-C,TG,Liver enzyme,CK,weight,qResults Results（结果）结果）:LDL-C减少:1.11mmol/L vs 0.28 mmol/L at 12 wks,0.93 mmol/L vs 0.39 m

19、mol/L at 24 wksqConclusion Conclusion（结论）结论）:Red yeast rice may be a treatment option for dislipidemic patients who cannot tolerate statin therapyBecher DJ,et al.Ann Intern Med 2009;150:830-839.Omega-3-fatty acids(Omega-3-fatty acids(-3-3-脂肪酸脂肪酸):):an an cardiovascular agent cardiovascular agentqLip

20、id-related effects:Lipid-related effects:dose-dependently reduce blood TGqPleiotropicPleiotropic effects:effects:favorable effects on inflammatory process,endothelial dysfunction,platelet aggregation and arrhythmogenesisqAdministration:Administration:used alone or used in combination with statinqMAC

21、E:MACE:need further study and more evidenceDimitrow PP,et al.Mini Rev Med Chem 2009;9:1030-1039.他汀类副作用他汀类副作用:除了停药还能作些什么？除了停药还能作些什么？小剂量他汀与降脂药物联合应用小剂量他汀与降脂药物联合应用 Combination of low-dose statin and Combination of low-dose statin and other lipid-lowering drugs other lipid-lowering drugs Adverse effects

22、of statins:Strategies beyond discontinuation小剂量他汀与其它调脂药物联合应用qBile acid Bile acid sequestrantssequestrants （多价螯合剂）多价螯合剂）(CholestyramineCholestyramine,colestipolcolestipol,colesevelamcolesevelam)qEzetimibeEzetimibeqNiacinNiacinqPlant sterolsPlant sterols（植物固醇）植物固醇）qFibrateFibrate (fenofibratefenofibra

23、te,bezafibratebezafibrate,gemfibrozilgemfibrozil)qOmega-3-fatty acids Omega-3-fatty acids（-3-3-脂肪酸）脂肪酸）Combination of low-dose statin and other lipid-lowering drugs 小剂量他汀与其它调脂药物联合应用q目的：维持达标水平,降低不良反应与事件q原则：小剂量他汀与另外一种降脂药物组成Combination of low-dose statin and other lipid-lowering drugs It has to stated

24、that for most of these combination therapies data on cardiovascular outcomes are still lacking.Fundam Clin Pharmacol 2009;14:88-94.临床上可供选择的联合治疗模式小剂量他汀类治疗LDL 未达到目标HDL 未达到目标TG 未达到目标*加用烟酸*加用贝特类药物 加用鱼油*=增加肌病危险性Grundy S,Am J Cardiol 2002;90:1135-38*加用烟酸*加用贝特类 加用伊折麦布*加用烟酸*加用贝特类药物Models of lipid-lowering c

25、ombination therapy依折麦布依折麦布+辛伐他汀辛伐他汀:显著降低显著降低LDL-C平均 变化%10 mg依10 mg+辛伐他汀10 mg80 mg40 mg20 mg辛伐他汀*联合治疗与单用他汀比较 p0.01Davidson,et al.J Am Coll Cardiol 2002;40:2125Davidson,et al.J Am Coll Cardiol 2002;40:2125More reduction of LDL-C levels following EZE+Simvastatin 依折麦布联合他汀治疗更有效降低CRPThomas P,et al.,Am J C

26、ardiol 2007;99:17061713.12 weeks therapyMore reduction of CRP levels following EZE+Simvastatin HATS:辛伐他汀与烟酸联用显著改善冠脉狭窄和心血管事件Zhao X et al.J Am Coll Cardiol.2002;39:242A;1130-73.Change in Stenosis,%CVD Event Rate,%*90%Reduction*代谢综合征n=69非代谢综合征n=7740%Reduction代谢综合征 n=77非代谢综合征 n=83*冠脉造影冠脉造影心血管事件心血管事件Plac

27、eboNiacin+SimvastatinMore reduction of MACE following niacin+simvastatin 他汀类副作用他汀类副作用:除了停药还能作些什么？除了停药还能作些什么？非他汀类降脂药物联合应用非他汀类降脂药物联合应用 Combination of non-statin lipid-lowering drugs Combination of non-statin lipid-lowering drugs Adverse effects of statins:Strategies beyond discontinuation非他汀降脂药物联合应用的临

28、床方向非他汀降脂药物联合应用的临床方向q Niacin-resin or fibrate-niacinq Extended-release niacin/laropipranq Squalene synthase inhibitor（角鲨烯合成 酶抑制剂）q Microsomal triglyceride transfer protein inhibitor（微粒体甘油三脂转运蛋白抑制剂）q antisense apolipoprotein B（反义载脂蛋白B）Novel nonstatin strategies to lower LDL-CCurr Atheroscler Rep 2009;

29、11:67-70.Extended niacin/laropiprant applicationqDesign:Design:Randomized,double-blind,placebo controlled Randomized,double-blind,placebo controlled multicenter,24-week trialmulticenter,24-week trialqDrug:Drug:Combination of Niacin 2000mg/laropiprant 40mg Combination of Niacin 2000mg/laropiprant 40m

30、gqResults:Results:LDL-C 18%LDL-C 18%Incidence and intensity of flushing were significantly reduced Incidence and intensity of flushing were significantly reduced compared with Niacin 2000mg pared with Niacin 2000mg alone.qConclusion:Conclusion:Combination of Niacin/Combination of Niacin/laropiprantl

31、aropiprant was generally was generally well tolerated by adults with well tolerated by adults with dyslipidemiadyslipidemia.Perry CM.Drugs 2009;69:1665-1679.Raising HDL-C with niacin and fibrates:a comparative reviewqDesign:Design:A head-to-head comparative study A head-to-head comparative studyqDru

32、g:Drug:Combination of Niacin 2,000mg/Gemfibrozil Combination of Niacin 2,000mg/Gemfibrozil 1,200mg compared with Niacin or 1,200mg compared with Niacin or FibrateFibrate trial alone trial aloneqIndexes:TC/HDL-C,Indexes:TC/HDL-C,LpLp(a)and fibrinogen (a)and fibrinogen qConclusion:Conclusion:Combinati

33、on therapies of Niacin plus a Combination therapies of Niacin plus a resin are effective,well tolerated,and safe.resin are effective,well tolerated,and safe.Sprecher D,Am J Cardiol 2001;86(suppl 1):46-50.他汀类副作用他汀类副作用:除了停药还能作些什么？除了停药还能作些什么？保护性药物的联合应用保护性药物的联合应用 Coenzyme Q10 supplementationCoenzyme Q10

34、 supplementationAdverse effects of statins:Strategies beyond discontinuation保护性药物联合应用的临床证据保护性药物联合应用的临床证据q Br J Clin Pharmacol 1996;42:333-337.q Ann Intern Med 2002;137:581-585.q Arch of Neurol 2004;61:889-892.q Eur J Clin Invest.2005;35:251-258.q Am J Cardiol 2004;94:1306-1310.q Georgian Medical New

35、s 2005(1):20-24.Clinical application of statin with preventive drugs 辅酶辅酶Q10Q10与他汀类药物的机制关系与他汀类药物的机制关系HMG-CoA甲酸戊酸甲酸戊酸异戊烯焦磷酸异戊烯焦磷酸焦磷酸法呢酯焦磷酸法呢酯辅酶辅酶Q10(CoQ10)多醇多醇胆固醇胆固醇鲨烯鲨烯HMGCoA还原酶HMGCoA还原酶抑制剂乙酰辅酶A+Possible Mechanism of Co-Q10 and statins 他汀类药物与他汀类药物与对辅酶对辅酶Q10Q10水平影响水平影响 Br J Clin Pharmacol 1996,42:333

36、高胆固醇血症患者(21岁-76岁，n=80）40名接受他汀类药物治疗，20名接受贝特类药物，20名没有药物治疗，20名健康对照者入住及试验一周后采集血样辛伐他汀(n=40)贝特类(n=20)未治疗患者(n=20)健康对照者(n=20)辛伐他汀贝特类 未治疗组健康对照组e P0.05 vs 未治疗组 h P0.05 vs 健康对照组Decreased levels of Co-Q10 in patients treated with statinMg l-1 0.75e 0.91h 0.95h 0.96辅辅酶酶Q Q1 10 0水水平平Statin-induced myopathy is ass

37、ociated with mitochondrion dysfunction 他汀性肌病与线粒体功能异常他汀性肌病与线粒体功能异常 Ann Intern Med.2002,137:581-585A,C,E服用他汀类药物肌肉活检图B、D、F 停药后肌肉活检图阿托伐他汀对辅酶阿托伐他汀对辅酶Q10Q10水平的影响水平的影响Decreased levels of Co-Q10 in patients treated with atorvastatinArchives of Neurology Vol.61(6):889-892*P0.01 与基线水平相比治疗后的天数2.01.81.61.41.21.

38、00.80.60.40.20基线 14 30 辅酶Q10的浓度(ug/mL)1.260.670.62*N=34阿托伐他汀80mg/天疗程30天辛伐他汀对辅酶辛伐他汀对辅酶Q10水平的影响水平的影响Effects of simvatstatin on plasma levels of Co-Q10 European Journal of Clinical Investigation.2005,35:251258辅酶Q10水平(nmol/L)时间（月）N=21辛伐他汀20mg/天疗程6个月，期间测定辅酶Q10的浓度停药一个月后，再测定体内辅酶Q10水平1500125010007505000 1 2

39、 3 4 5 6 7*P0.05,与基线相比vs服用他汀类药物的患者 DT值,#p=0.002,$p=0.12DT值14位高脂血症患者51-79岁，他汀类药20mg/天，疗程 3-6个月10名患者出现心室舒张功能恶化再加用辅酶Q10 300mg/天(100mg/次，tid)后，患者心肺功能得到恢复Silver MA,et al.Am J Cardiol 2004,94:1306-1310 192#209$242 基线 他汀类药物他汀类药物+辅酶Q10Statin plus Co-Q10 reverse statin-induced ventricular dysfunction 辅酶辅酶Q10

40、逆转他汀引起的心室舒张功能逆转他汀引起的心室舒张功能 基线 他汀类药物+辅酶Q10 他汀类药物组小结小结:他汀副作用除了停药可以选择策略他汀副作用除了停药可以选择策略q 减量与间断应用减量与间断应用 q 他汀类药物之间的转换应用他汀类药物之间的转换应用 q 非他汀降脂药物的替换应用非他汀降脂药物的替换应用q 小剂量他汀与降脂药物联合应用小剂量他汀与降脂药物联合应用 q 保护性药物的联合应用保护性药物的联合应用温馨提示：上述策略的循证证据十分有限，本内容仅供学术研讨Summary:Adverse effects of statins:Strategies beyond discontinuationBuilding insights,break boundaries更多医学精品更多医学精品尽在医学吧尽在医学吧